Antares Pharma's Oral Testosterone Treatment Scores FDA Approval
- Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of.
- 03/29/2022
|
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript
- Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript
- 03/03/2022
|
Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates
- Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/03/2022
|
Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
- EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42nd Annual Healthcare Conference being held on March 7-9, 2022.
- 02/28/2022
|
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
- EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.
- 02/17/2022
|
A Look At Recent Moves By Antares Pharma
- Antares is a company I've followed for years, and I recently decided to reinitiate a position. That's because the stock price has fallen significantly with the broader market while management has made several big moves lately that I really liked.
- 01/24/2022
|
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
- The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.
- 01/18/2022
|
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript
- Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Antares Pharma (ATRS) Reports Next Week: What to Expect
- Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/28/2021
|
Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
- EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens.
- 10/21/2021
|
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
- Pharmacokinetic data results expected in 1Q 2022 Pharmacokinetic data results expected in 1Q 2022
- 09/30/2021
|
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
- EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held on September 13-15, 2021.
- 09/08/2021
|
Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying
- These healthcare stocks have their warts, but the price is right for long-term investors.
- 08/27/2021
|
Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript
- Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
Antares Pharma Reports Second Quarter 2021 Financial and Operating Results
- Increased Revenue 39% Year-Over-Year to $45.0 Million
- 08/05/2021
|
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results
- EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens.
- 07/28/2021
|
Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue
- EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue. The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.
- 07/22/2021
|
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
- Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.
- 07/05/2021
|
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
- Ad hoc announcement pursuant to Art. 53 LR
- 06/28/2021
|
Antares Pharma to Present at the Raymond James Human Health Innovations Conference
- EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Raymond James Human Health Innovations Conference.
- 06/15/2021
|
Antares Pharma to Present at the Jefferies Virtual Healthcare Conference
- EWING, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference.
- 05/26/2021
|
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2021 Results - Earnings Call Transcript
- Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Antares Pharma (ATRS) Meets Q1 Earnings Estimates
- Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 2.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial
- EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.
- 05/06/2021
|
Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting
- EWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hypogonadal populations was presented in a poster presentation at the Pediatric Endocrine Society (PES) 2021 Virtual Annual Meeting on April 30 – May 3, 2021.
- 05/03/2021
|
Antares Pharma to Report First Quarter 2021 Financial and Operating Results
- EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the market opens.
- 04/27/2021
|
Antares Pharma - Why It's A $4 Stock (And Might Remain So)
- Antares Pharma operates in crowded markets with relatively low barriers to entry and intense competition. Their flagship product, XYOSTED, grew significantly in 2019 and 2020 but competitors may enter the market as soon as October 2021.
- 04/26/2021
|
Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer
- EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the Company's proprietary research and development programs, including ideation, formulation, clinical operations, pharmacovigilance and medical affairs.
- 04/26/2021
|
A Trio of Stock Picks for the Value Investor
- In my opinion, choosing U.S.-listed securities that have the following characteristics represents a solid starting point when looking for potential value opportunities:
- 04/11/2021
|
Antares Pharma's (ATRS) CEO Bob Apple on Q4 2020 Results - Earnings Call Transcript
- Antares Pharma's (ATRS) CEO Bob Apple on Q4 2020 Results - Earnings Call Transcript
- 03/02/2021
|
Antares Pharma (ATRS) Q4 Earnings Lag Estimates
- Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/02/2021
|
Recap: Antares Pharma Q4 Earnings
- Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the estimate of $0.03.
- 03/02/2021
|
Antares Pharma to Present at Two Upcoming Investor Conferences
- EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present and host investor meetings at the Raymond James 42nd Annual Virtual Institutional Investors Conference and the Cowen 41st Annual Virtual Healthcare Conference.
- 02/24/2021
|
Antares Pharma to Report Fourth Quarter and Full-Year 2020 Financial and Operating Results
- EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year 2020 financial and operating results on Tuesday, March 2, 2021, before the market opens.
- 02/23/2021
|
Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference
- EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the SVB Leerink 10th Annual Virtual Global Healthcare Conference being held on February 22-26, 2021.
- 02/17/2021
|
3 Top Stocks Trading Under $5 a Share
- These interesting low-cost stocks have the opportunity to grow.
- 12/25/2020
|
3 Top Stocks Under $5
- These companies offer more potential than the stock price might indicate.
- 11/28/2020
|
Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
- EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020.
- 11/23/2020
|
Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference
- EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer is scheduled to present at the Jefferies Virtual London Healthcare Conference.
- 11/10/2020
|
Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript
- Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript
- 11/05/2020
|
Reviewing Lyra Therapeutics (NASDAQ:LYRA) & Antares Pharma (NASDAQ:ATRS)
- Lyra Therapeutics (NASDAQ:LYRA) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Analyst Recommendations This is a summary of current ratings and price targets for Lyra Therapeutics […]
- 08/11/2020
|
Antares Pharma Appoints Tram Bui as Vice President of Corporate Communications and Investor Relations | MarketScreener
|
Antares Pharma Appoints Tram Bui as Vice President of Corporate Communications and Investor Relations
- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Tram Bui as Vice President of
- 08/10/2020
|
Antares Pharma Appoints Tram Bui as Vice President of Corporate Communications and Investor Relations
- Jack Howarth Retires as Vice President of Corporate AffairsEWING, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Tram Bui as Vice President of Corporate Communications and Investor Relations. Ms. Bui will succeed Jack Howarth, Vice President of Corporate Affairs, upon his retirement on August 31, 2020. Tram will report to Fred Powell, Antares Pharma’s Chief Financial Officer.“I am excited to welcome Tram to Antares to lead our corporate communications and investor relations strategy. We look forward to leveraging her extensive industry experience and strong relationships with the investment community as the Company continues on its growth trajectory,” said Fred M. Powell, Executive Vice President and Chief Financial Officer of the Company. “I would also like to thank Jack for his dedication and many contributions to the company since 2012. He has been instrumental to the development of the Company’s communications strategy and we wish him the best of luck in his retirement.” Ms. Bui joins Antares Pharma with over 15 years of equity research, communications and investor relations experience. Most recently, she served as Senior Vice President, Investor Relations at The Ruth Group, a boutique investor relations and communications firm specializing in life science and medical technology industries. Prior to The Ruth Group, Ms. Bui served as a Director at KCSA Strategic Communications, a public and investor relations agency, focused on developing successful investor communications platforms and capital raises for a broad base of public healthcare companies. Previously, she was a buy-side healthcare analyst for a small cap fund at Lazard Asset Management and served as an institutional equity sales associate at CJS Securities. Ms. Bui received her Bachelor of Science in Marketing from the University of New Orleans.About Antares PharmaAntares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: Teva’s successful commercialization of teriparatide injection in Europe and future revenue from the same; the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on reinstated 2020 full-year revenue guidance, demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same; the ability of Lunatus to obtain regulatory approvals for XYOSTED in Saudi Arabia and UAE and successfully commercialize the product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.’s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development; actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.Contact:Tram Bui Vice President, Corporate Communications and Investor Relations 609-359-3020 tbui@antarespharma.com
- 08/10/2020
|
A Quick Analysis On Antares Pharma's (NASDAQ:ATRS) CEO Compensation
- Bob Apple became the CEO of Antares Pharma, Inc. (NASDAQ:ATRS) in 2016, and we think it's a good time to look at the...
- 08/07/2020
|
Antares Pharma : Reports Strong Second Quarter 2020 Operating and Financial Results, Reinstates Full-Year 2020 Revenue Guidance | MarketScreener
|
Antares Pharma Reports Strong Second Quarter 2020 Operating and Financial Results; Reinstates Full-Year 2020 Revenue Guidance
- * Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019 * Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019 * Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 MillionEWING, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today reported operating and financial results for the second quarter ended June 30, 2020 with record second quarter revenue of $32.4 million and net income of $2.2 million, or earnings per share of $0.01. The Company also reported record six-month year-to-date revenue of $65.5 million, a 27% increase versus the first six months of 2019.“I am very proud of the Antares team for delivering strong quarterly results while navigating the challenges presented by the COVID-19 pandemic. We remain committed to protecting the health and safety of our employees, patients, and health care providers while effectively operating our business to meet the needs of our partners and patients during this unprecedented time. The Company’s second quarter revenue of $32.4 million, which represents 14% year-over-year growth, was primarily driven by our proprietary product XYOSTED. The second quarter had the highest number of XYOSTED prescriptions to date, and we believe this is the result of the tremendous execution by our commercial team and highlights the demand for an easy to use, painless at-home testosterone injection option given limited physician and patient access at this time. Revenue from proprietary products, XYOSTED and OTREXUP, our highest margin products, grew 65% in the quarter versus the same period last year and now represent 60% of our total product revenue,” said Robert F. Apple, President and Chief Executive Officer of the Company.“We also continued to advance our product pipeline with the recently launched Teriparatide Injection (“teriparatide”) by Teva, the generic version of Eli Lilly’s brand Forsteo, in Canada and certain countries in Europe. According to Teva, the initial launch of teriparatide, which utilizes our multi-dose pen technology, will expand into other European countries later this year. Additionally, we look forward to a potential U.S. approval of a generic Forteo later this year. Finally, while the pandemic continues to pose some uncertainty for the second half of the year, we are encouraged by the growth of our business and the opportunities ahead, and therefore we have reinstated our revenue guidance for the full year,” Mr. Apple concluded.Second Quarter 2020 and Recent Highlights * Reported second quarter total 2020 revenue of $32.4 million, an increase of 14% compared to the same period last year. Proprietary product revenue increased 65% to $14.8 million as compared to $9.0 million in the second quarter of 2019. Reported second quarter 2020 earnings per share of $0.01 as compared to a $0.01 loss per share reported in the comparable period last year. * According to Symphony Health Solutions, XYOSTED® total prescriptions increased 11% sequentially versus the first quarter of 2020. Since the product launched, more than one hundred thirty-two thousand prescriptions of XYOSTED® have been written by almost six thousand different physicians. * Announced the first commercial product using Antares Pharma’s multi-dose pen platform was launched by the Company’s development partner Teva Pharmaceutical Industries, Ltd. Teriparatide Injection, the generic version of Eli Lilly’s brand product Forsteo® was launched in Austria, Croatia, Denmark, Hungary, Ireland, The Netherlands, Portugal, Sweden, Switzerland, The United Kingdom as well as Canada and Israel. Teva has indicated they expect to launch in other European countries later this year. * Announced an exclusive distribution agreement with Lunatus Global Medical Supplies to register, promote and distribute XYOSTED® in Saudi Arabia and the United Arab Emirates. * Cash, cash equivalents and short-term investments increased to $51.6 million at June 30, 2020, compared to $45.7 million at December 31, 2019.Second Quarter 2020 Financial ResultsTotal revenue generated from product sales, development activities and royalties was $32.4 million for the three months ended June 30, 2020, a 14% increase compared to $28.4 million in the same period in 2019. For the six months ended June 30, 2020, total revenue was $65.5 million, a 27% increase from $51.7 million for the comparable period in 2019.Product sales were $24.7 million for the three months ended June 30, 2020, a 20% increase compared to $20.6 million for the same period in 2019. For the six-month period ended June 30, 2020, product sales were $51.8 million, a 33% increase from $38.9 million in the comparable period in 2019. Sales of our proprietary products XYOSTED® and OTREXUP® generated revenue of $14.8 million and $27.4 million for the three and six months ended June 30, 2020, respectively, as compared to $9.0 million and $13.8 million for the three and six months ended June 30, 2019, respectively. The 65% and 99% increase in proprietary product sales for the three and six months ended June 30, 2020 respectively, compared to the three and six months ended June 30, 2019 were principally attributable to sales of XYOSTED®. Partnered device sales were $9.8 million and $11.6 million for the three months ended June 30, 2020 and 2019, respectively, and $24.4 million and $25.2 million for the six months ended June 30, 2020 and 2019, respectively. The decrease in sales of partnered products for the three and six months ended June 30, 2020 as compared to the same period in 2019 is primarily attributable to a decrease in sales of needle-free devices to Ferring, and a decrease in sales of Sumatriptan Injection USP and teriparatide devices to Teva. Antares previously announced the divestiture of the needle-free device to Ferring and shipment of pre-launch quantities of teriparatide devices to Teva during the first two quarters of 2019.Licensing and development revenue was $2.7 million and $4.4 million for the three and six-month periods ended June 30, 2020, respectively, compared to $2.2 million and $3.2 million for the comparable periods in 2019, respectively. Licensing and development revenue for the three and six- month periods was primarily from the Pfizer rescue pen and the Idorsia selatogrel pen development programs.Royalty revenue was $5.0 million for the three months ended June 30, 2020 compared to $5.6 million for the same period in 2019. For the six-month period ended June 30, 2020, royalty revenue was $9.3 million, compared to $9.6 million for the same period in 2019. The decrease in royalty revenue for the three and six-month periods were primarily attributable to a decline in royalties recognized from AMAG on their net sales of the Makena® subcutaneous auto injector.Operating expenses were $16.9 million for the second quarter of 2020 compared to $17.6 million in the comparable period of 2019. Total operating expenses for the six months ended June 30, 2020 were $36.3 million as compared to $34.9 million for the comparable period in 2019. The increase in operating expenses for the six-month period of 2020 as compared to the same period in 2019 was primarily attributable to increased head count as well as increased non-cash incentive compensation expense.Net income was $2.2 million, or $0.01 per share for the second quarter of 2020, compared to a net loss of $2.2 million, or $0.01 per share in the same period in 2019. Net loss was $0.2 million, or $0.00 per share for the six months ended June 30, 2020 compared to a net loss of $7.8 million, or $0.05 per share in the comparable period of 2019. At June 30, 2020, cash, cash equivalents and short-term investments were $51.6 million compared to $45.7 million at December 31, 2019.2020 Financial GuidanceThe Company today reinstated 2020 full-year revenue guidance in a range of $135 to $155 million, which represents a 9% to 25% year-over-year growth rate. Given the unprecedented and unpredictable environment created by the COVID-19 pandemic, we reserve the right to revisit revenue guidance at some future point in time.Webcast and Conference Call InformationAntares executives will provide a Company update and review second quarter 2020 financial results via webcast and conference call today, August 6, 2020, at 8:30 a.m. ET (Eastern Time). The webcast of the conference call, which will include a slide presentation, can be accessed through the link located on the “For Investors” section of the Company’s website (www.antarespharma.com) under “Webcasts & Presentations”. Alternatively, callers may participate in the audio portion of the conference call by dialing toll free 1-800-353-6461, or 1-334-323-0501. Callers should reference the Antares Pharma conference call or conference identification code 5888699. Callers can access the slide presentation on the “For Investors” section of the Company’s website under “Webcasts & Presentations”. A telephone replay of the conference call will be available from 11:30 a.m. ET on Thursday, August 6, 2020 through 11:30 a.m. ET on Saturday, September 5, 2020. To access the replay, callers should dial 1-888-203-1112 or 1-719-457-0820 and enter passcode 5888699. About Antares PharmaAntares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.
- 08/06/2020
|
Did Hedge Funds Make The Right Call On Antares Pharma Inc (ATRS)?
- We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
- 08/03/2020
|
Antares Pharma and Lunatus Enter Into an Exclusive Distribution Agreement for XYOSTED® in Saudi Arabia and the United Arab Emirates
- EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies (“Lunatus”) to distribute and promote the sale of XYOSTED® in Saudi Arabia and the United Arab Emirates (“UAE”). Under the agreement, Antares will be responsible for the supply of fully packaged product to Lunatus and Lunatus will be responsible for submitting and obtaining regulatory approval for XYOSTED® in Saudi Arabia and the UAE as well as marketing, promotion and distribution of XYOSTED® in these two countries.“We believe today’s announcement represents the first step in creating increased brand awareness for XYOSTED in the rest of the world, and look forward to working with our partner Lunatus in that endeavour. XYOSTED is currently the fastest growing branded testosterone replacement therapy in the U.S.,” said Robert F. Apple, President and Chief Executive Officer of the Company.” He continued, “Current treatment options in these two countries include a painful hospital administered testosterone injection given every three months or a topical gel. Alternatively, XYOSTED would be an attractive new treatment option for physicians and patients given its unique product profile featuring a virtually painless, once-weekly, at-home subcutaneous self-injection. Lunatus, a Dubai based company, has a proven track record of introducing, building and maintaining profitable brands in the Arabian Gulf and Middle East regions. We believe this agreement will help lay the groundwork for expanding our global footprint for XYOSTED and represents the first of potentially multiple international distribution agreements.”“We are excited to bring XYOSTED to Saudi Arabia and the UAE. XYOSTED is a U.S. FDA approved treatment option for adult men diagnosed with testosterone deficiency,” said Dr. Lina Kouatly, President and Chief Executive Officer of Lunatus. “Assuming regulatory approval in these two countries, we believe our partnership can achieve significant share and expand the market using this novel treatment approach.” About Antares PharmaAntares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s proprietary products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: Lunatus’ ability to obtain regulatory approval and successfully commercialize XYOSTED in Saudi Arabia and the United Arab Emirates and the amount of revenue from the same, the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.’s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development; actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.Contacts:Jack Howarth Vice President, Corporate Affairs 609-359-3016 jhowarth@antarespharma.com
- 08/03/2020
|
SG Americas Securities LLC Raises Stock Holdings in Antares Pharma Inc (NASDAQ:ATRS)
- SG Americas Securities LLC increased its position in Antares Pharma Inc (NASDAQ:ATRS) by 109.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,869 shares of the specialty pharmaceutical company’s stock after acquiring an additional 154,049 shares during the period. SG Americas Securities […]
- 08/03/2020
|
Spaceflight Inc. Reveals Ground-Breaking Launch Initiatives to Provide Greater Flexibility, Mitigate Delays, and Meet Specific Mission Needs
- Spaceflight Inc., the leading satellite rideshare and mission management provider, today announced, during the opening of Small Satellite Conference 2
- 08/03/2020
|
Antares Pharma to Report Second Quarter 2020 Operating and Financial Results
- EWING, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020. Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 6, 2020 to discuss the results. Interested parties may participate in the conference call by dialing 1-800-353-6461 or 1-334-323-0501 and entering access code 5888699. We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time. A replay of the conference call will be available from 11:30 a.m. ET on Thursday, August 6, 2020 through 11:30 a.m. ET on Saturday, September 5, 2020 by dialing 1-888-203-1112 or 1-719-457-0820 and entering the access code 5888699. An archive of the slide presentation will also be available under the “For Investors” section of the Antares Website at www.antarespharma.com.About Antares PharmaAntares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s proprietary products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same and the impact on demand for our products, new patients and prescriptions, future revenue, product supply, and our overall business, operating results and financial condition; market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.’s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development; actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.Contacts: Jack Howarth Vice President, Corporate Affairs 609-359-3016 jhowarth@antarespharma.com
- 07/30/2020
|
Transdermal Drug Delivery Market Analysis 2020-2027 and the Expected Impact of COVID-19 - ResearchAndMarkets.com
|
First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Launches in Europe
- EWING, N.J., July 21, 2020 -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the.
- 07/21/2020
|
Antares Pharma Appoints Patrick Shea Senior Vice President of Commercial
- EWING, N.J., July 20, 2020 -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the.
- 07/20/2020
|
Anteres Capital Hit With Layoffs as Deals Slide
- Antares Capital, the former lending unit of GE Capital, has laid off 10% of its staff or about 40 people, according to people familiar with the situation.
- 07/16/2020
|
Antares Continues To Quietly Grow Revenue
- Antares Pharma reported strong growth in Q1 2020 despite the COVID-19 pandemic. The company has two additional partnered products that could get approved within the next year, and now it looks like Makena may not get removed from the market after all.
- 07/15/2020
|
Spaceflight Inc. Unveils Next-Gen Orbital Transfer Vehicle to Fly Aboard Next SpaceX Rideshare Mission
- Spaceflight Inc., the leading satellite rideshare and mission management provider, announced today that it will be flying its next generation orbital
- 07/15/2020
|
Antares Supports GreyLion Capital’s Acquisition of Metal Era
- Antares announced today that it served as sole lead arranger and sole lender on $65 million in senior secured credit facilities to support the acquisi
- 07/13/2020
|
Antares Pharma Inc (NASDAQ:ATRS) Stock Holdings Lowered by Parametric Portfolio Associates LLC
- Parametric Portfolio Associates LLC reduced its holdings in Antares Pharma Inc (NASDAQ:ATRS) by 78.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,598 shares of the specialty pharmaceutical company’s stock after selling 247,290 shares during the quarter. Parametric Portfolio Associates LLC’s holdings […]
- 07/12/2020
|
AQR Capital Management LLC Acquires 48,995 Shares of Antares Pharma Inc (NASDAQ:ATRS)
- AQR Capital Management LLC raised its holdings in Antares Pharma Inc (NASDAQ:ATRS) by 102.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,706 shares of the specialty pharmaceutical company’s stock after purchasing an additional 48,995 shares during the quarter. AQR Capital Management […]
- 07/12/2020
|
For Your Naked Eyes Only: 7 Stars, Planets And A Comet Anyone Can Find In The Night Sky This Weekend
- Locate all of these targets—including Jupiter and Comet NEOWISE—and you’ll have discovered the perfect socially distanced ways to enjoy your summer staycation among the stars.
- 07/09/2020
|
QIC Global promotes Alexander Craggs to CEO at Antares - Reinsurance News
- QIC Global, the international specialty re/insurance arm of Qatar Insurance Group, has named Alexander Craggs as acting Chief Executive Officer (CEO) and
- 07/08/2020
|
Antares Supports Quad-C Management’s PRISM Vision Group as It Acquires The Retina Group of Washington
- Antares announced today that it served as joint lead arranger and is acting as administrative agent on $330 million in senior secured credit facilitie
- 07/06/2020
|
‘Buck Moon’ Wanes As Bright Planets Peak: What You Can See In The Night Sky This Week
- The celestial highlights for the week ahead.
- 07/05/2020
|
Unprecedented Astronomy: Atmosphere of the Red Supergiant Star Antares Revealed by Radio Telescopes
- An international team of astronomers has created the most detailed map yet of the atmosphere of the red supergiant star Antares. The unprecedented sensitivity and resolution of both the Atacama Large Millimeter/submillimeter Array (ALMA) and the National Science Foundation’s Karl G. Jansky Very Larg
- 07/04/2020
|
Comparing Antares Pharma (NASDAQ:ATRS) & STRATA Skin Sciences (NASDAQ:SSKN)
- Antares Pharma (NASDAQ:ATRS) and STRATA Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Risk & Volatility Antares Pharma has a beta of 1.36, meaning that its stock […]
- 07/03/2020
|
How Saturn saved the earth
- After saving us from a greedy Jupiter, the story of the ringed-gas giant and our blue planet has basically been written in the stars since the beginning, writes Nigel Henbest
- 07/01/2020
|
4th Of July ‘Buck Moon’ Is Third Lunar Eclipse Of 2020, Second In Weeks And First Visible In The US
- Saturday night's ‘Buck Moon Eclipse’ Is the first of three big cosmic sights visible in the night sky in July 2020.
- 06/30/2020
|
Starwatch: the time of the scorpion
- Now is the time for stargazers in the northern hemisphere to get their best view of the southern zodiacal constellation Scorpius
- 06/28/2020
|
Nova etapa de distribuição de cestas básicas começa com longas filas em Maceió
- Beneficiários devem retirar a cesta no ponto mais próximo de casa até o dia 4 de julho ou enquanto houver cestas, para evitar aglomeração.
- 06/25/2020
|
3 "Strong Buy" Penny Stocks With Triple-Digit Upside Potential
- COVID-19 and the ensuing economic shutdowns have changed the rules of the investing game. Amid this unprecendented market shakeup, investors must navigate
- 06/24/2020
|
3 “Strong Buy” Penny Stocks That Could See Outsized Gains
- COVID-19 and the ensuing economic shutdowns have changed the rules of the investing game. Amid this unprecendented market shakeup, investors must navigate unfamiliar territory, with the old saws not necessarily as reliable as they were before. According to Bank of America, one of these investing playbook staples is the often-repeated phrase, “sell in May and go away.” Even though the S&P; 500’s charge forward had reached somewhat of a standstill, this week has seen the index post a two-day winning streak, and the firm thinks there’s still plenty of room for a summer rally.“...seasonality favors a summer rally as contrarian bullish Farrell Sentiment and futures positioning across large speculators, leveraged funds and asset managers suggest that the pain trade remains higher and equities continue to climb a perpetual wall of worry,” Bank of America strategists wrote. “The second best 3-month period of the year for the S&P; 500 going back to 1928 is June - August, which has been up 64% of the time with an average return of 3.1%. Within this bullish three-month period, most of the fireworks occur in July, which has been up 59% of the time with an average return of 1.5%.” The firm’s conclusion? “Sell in July/August.”Taking all of this into consideration, we used TipRanks’ database to find compelling penny stocks, or names trading for less than $5 per share. These tickers are notoriously risky, so we kept our eyes peeled for only the crème de la crème. The platform revealed three that met our criteria, each boasts a “Strong Buy” consensus rating from the analyst community as well as significant upside potential.ConforMIS (CFMS)Applying a new approach to orthopedics, ConforMIS combines advanced 3D imaging technology with the latest manufacturing capabilities to produce implants based on each patient’s unique size and shape. While COVID-19 has taken a toll on the company, several analysts think that at $0.79 per share, now is the time to get in on the action.Canaccord analyst Kyle Rose is among the CFMS bulls, noting: “Our view continues to be that while elective procedure volumes will likely be significantly depressed through at least Q2, we will see quarter-over-quarter improvements with gains dramatically rising in the back half of the year (normalization likely in the Q4 or early 2021). We continue to view the LT opportunity of custom orthopedic implants favorably, particularly in a backdrop that includes growing expectations for the shift of procedures into the ASC/ outpatient setting – a setting which favors CFMS's ‘implant-in-a-box' product offering.”Speaking to the company’s standing before the pandemic’s onset, Rose points out that “underlying execution was trending positively.” Originally, Q1 revenue was expected to reflect a 3% year-over-year decline, significantly better than the actual 20.2% drop. This slowdown persisted throughout April, with its peers outperforming the company as CFMS derives more of its revenue from primary elective procedures. However, management did see an uptick in order volumes during the last week of April and first week of May.“The company expects procedures to continue trending higher in the back half of the year, with base case assumptions being that Q4 is flat to down ~10% and the U.S. returns to normalized volumes quicker than Europe. Management also believes the shift of orthopedic surgery toward the outpatient/ASC setting accelerates (something we've heard from other ortho companies and physicians we've surveyed), representing a tailwind for the company given its exposure there,” Rose noted.With CFMS also expecting its development agreement with SYK's Triathlon system to be commercially available mid-2021, the deal is sealed for Rose. In line with his optimistic take, the analyst reiterated a Buy rating and $2 price target. Should the target be met, a twelve-month gain of 152% could be in store. (To watch Rose’s track record, click here) Do other analysts agree with Rose? As it turns out, most do. 3 Buy ratings and a single Hold add up to a Strong Buy analyst consensus. At $2.33, the average price target indicates 194% upside potential. (See ConforMIS stock analysis on TipRanks)Antares Pharma (ATRS)Combining drug development expertise with patented delivery technology, Antares Pharma wants to provide safe and effective therapies that improve dosing and reduce side effects. Following a strong showing in its first quarter, multiple members of the Street believe that its $2.91 share price reflects an attractive entry point.Writing for Ladenburg, analyst Matthew Kaplan tells clients that the reported Q1 revenue of $33.1 million flew past his $30.6 million call. It should be noted that this revenue excludes propriety products including XYOSTED and OTREXUP, which generated revenue of $9 million and $3.6 million, respectively. Sales from its partnered products and from the auto-injector, multi-dose pen and needle-free products also weren’t included.Looking specifically at XYOSTED’s January 2019 launch, Kaplan believes it “continues to be very encouraging, and we continue to believe it could become the primary driver of topline growth.”The analyst added, “XYOSTED prescriptions continue to grow with over 100,000 prescriptions filled since launch by 5,300 unique prescribers, with greater than 19,000 patients prescribed XYOSTED. Growth was supported by an increased co-pay assistance program at the start of the year to bridge patients through reauthorizations. ATRS has achieved payer coverage of ~72% of commercial lives as of the end of Q1 2020.”Although the uncertainty surrounding COVID-19's impact caused ATRS to withdraw its 2020 revenue guidance, Kaplan maintained his estimates. “Despite the impact of near-term reimbursement authorizations and COVID-19, we see the rise of telemedicine and need to avoid intramuscular injections as positive developments for XYOTSTED uptake. With respect to the Makena SC auto-injector royalty and device revenues and the ADCOM outcome, we believe there is relatively little risk the FDA will remove the product from the market given otherwise unmet need in the space and FDA approved, non-compounded formulations,” he explained.Adding to the good news, Kaplan sees multiple potential catalysts for ATRS in 2020 including continued XYOSTED and generic EpiPen prescription growth, potential FDA approval and launch of generic Forteo and additional visibility to pipeline products in development. It also doesn’t hurt that developmental activities are progressing, with COVID-19 having a relatively limited effect.Everything that ATRS has going for it prompted Kaplan to stay with the bulls. Along with a Buy recommendation, he left his price target at $7. This target implies shares could climb 141% higher in the next year. (To watch Kaplan’s track record, click here) Other analysts also take a bullish approach. Antares’ Strong Buy consensus rating breaks down into 4 Buys and zero Holds or Sells. Additionally, the $6.13 average price target puts the potential twelve-month gain at 111%. (See Antares stock analysis on TipRanks)Celsion Corporation (CLSN)Operating within the oncology space, Celsion uses its cutting-edge technologies and unique targeting strategies to develop therapies that could potentially improve survival rates or even cure cancers. Currently going for $4.44 apiece, some Wall Street pros warn investors not to miss out on an exciting opportunity.Representing Oppenheimer, five-star analyst Hartaj Singh is optimistic prior to its readout of the second interim analysis of the Phase 3 OPTIMA trial evaluating ThermoDox in hepatocellular carcinoma (HCC) in Q3 2020. He doesn’t dispute the fact that the trial has a “complicated history”, with it having an unsuccessful first interim in Q4 2020.Looking more closely at the trial, it was designed based on the Phase 3 failure of the HEAT trial in early 2013. “We note that recent reviews of historical data indicates a ~35% chance of Phase 3 success in oncology trials. However, we believe that CLSN's HEAT trial served as a large Phase 2 proof of concept (PoC) trial, letting CLSN learn from mistakes and potentially position ThermoDox for success in this underserved population,” Singh explained.As for why Singh is bullish this time around, and assigns a 50% chance of success compared to 33% for the first interim, he stated, “Given better statistical odds for the second interim, larger number of patient events and a longer patient follow-up, we believe OPTIMA tees up better for the second interim.”Going forward, if the trial is successful, Singh argues investor focus will land squarely on the significant potential of ThermoDox in primary HCC. “Our physician checks have indicated that radio frequency ablation (RFA) is a low-risk procedure with a high risk of disease recurrence—two areas that a positive OPTIMA trial could address. We believe our modeling of ThermoDox's potential in HCC could be conservative,” the analyst said.Based on all of the above, it’s no wonder Singh reiterated his Outperform rating. With a $9 price target, shares could soar 109% in the next twelve months. (To watch Singh’s track record, click here) Looking at the consensus breakdown, other analysts are on the same page. With 3 Buys and no Holds or Sells, the word on the Street is that CLSN is a Strong Buy. Given its $7 average price target, upside of 62% could be in store for investors. (See Celsion stock analysis on TipRanks)To find good ideas for penny stocks stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 06/24/2020
|
Hedge Funds Have Never Been This Bullish On Antares Pharma Inc (ATRS)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/22/2020
|
How To Sync Your Summer With The Stars: The 17 Biggest Sights You Can Discover From Home This Season
- Astronomical summer has begun in the northern hemisphere. Here's how to find your way amongst the stars on warm summer nights.
- 06/20/2020
|
Assessment of COVID-19's Effect on Needle-Free Drug Delivery Devices Market 2020-2024 | Technological Advances in Needle-Free Drug Delivery Devices to Augment Growth | Technavio
|
Assessment of COVID-19's Effect on Needle-Free Drug Delivery Devices Market 2020-2024 | Technological Advances in Needle-Free Drug Delivery Devices to Augment Growth | Technavio
- The Global Needle-free Drug Delivery Devices Market will grow by USD 10.23 bn during 2020-2024
- 06/19/2020
|
España, nuestro destino favorito
- El julio de color lavanda en Brihuega, un viaje en coche por los miradores gallegos o un bosque convertido en museo en Lleida. Planes muy tentadores para disfrutar del verano cerca de casa
- 06/18/2020
|
Spaceflight Inc. Signs Multi-Launch Agreement with SpaceX for Rideshare Services
- Spaceflight Inc., the leading satellite rideshare and mission management provider, today announced it inked an agreement with SpaceX to secure ridesha
- 06/17/2020
|
ANTARES PHARMA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) | MarketScreener
|
Spaceflight Inc. Acquisition Finalized
- Today satellite rideshare launch provider Spaceflight Inc. announced its acquisition by Mitsui & Co., Ltd., in partnership with Yamasa Co., Ltd.,
- 06/12/2020
|
Antares Pharma to Present at the Raymond James Human Health Innovation Conference
- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond
- 06/11/2020
|
Russell Investments Group Ltd. Raises Holdings in Antares Pharma Inc (NASDAQ:ATRS)
- Russell Investments Group Ltd. boosted its stake in shares of Antares Pharma Inc (NASDAQ:ATRS) by 300.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 173,156 shares of the specialty pharmaceutical company’s stock after acquiring an additional 129,875 shares during the […]
- 06/10/2020
|
Stargazing in June: The clouds are shining brightly
- ‘Tis the season of spotting glow-in-the-dark clouds, so keep an eye open for those in the night sky
- 06/03/2020
|
Strawberry moon - when is the June full moon 2020 and how it gets its name
- Lockdown has made many of us more enthusiastic about stargazing and there's a Strawberry Moon coming - this is how to see it
- 06/02/2020
|
Starwatch: a subtle shadow on the face of the moon
- Less spectacular than a total eclipse but no less interesting, the penumbral lunar eclipse to be seen on Friday will be well worth watching
- 05/31/2020
|
Cumberland Pharmaceuticals: All-Time Lows Look Deserved (NASDAQ:CPIX)
- Cumberland finally has executed on its professed strategy of picking up approved drugs neglected by larger players. The problem is that the strategy hasn't nece
- 05/28/2020
|
Why Is This Fast-Growing Biotech So Undervalued?
- Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?
- 05/28/2020
|
Antares Pharma to Present at the Jefferies Virtual Healthcare Conference
- Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:00 a.m. Eastern Time. Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).
- 05/27/2020
|
Antares Pharma to Present at the Jefferies Virtual Healthcare Conference
|
Edited Transcript of ATRS earnings conference call or presentation 5-May-20 12:30pm GMT
- Q1 2020 Antares Pharma Inc Earnings Call
- 05/26/2020
|
Methotrexate Injection Market Demand and Precise Outlook 2020-2026 | Hikma, Teva, Accord, Fresenius Kabi, Mylan, Pfizer, Get Well Pharmaceutical, Sichuan Huiyu Pharma
- May 25, 2020 (Market Insight Reports) --
The report presents an in-depth assessment of the Methotrexate Injection including enabling technologies, key...
- 05/25/2020
|
Antares Pharma Inc (NASDAQ: ATRS) Q1 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of Antares Pharma Inc. - ATRS stock
- 05/21/2020
|
Edited Transcript of ATRS earnings conference call or presentation 5-May-20 12:30pm GMT
- Q1 2020 Antares Pharma Inc Earnings Call
- 05/21/2020
|
Top Pharmaceutical Company Visionaries to Keynote Veeva Summit Online
- Alnylam and Pfizer to discuss how innovative oncology and specialty medicines are transforming commercial models and helping improve patients' lives
- 05/21/2020
|
Healthcare Value Capital, LLC Buys ProShares UltraPro Short S&P5……, AstraZeneca PLC, ...
|
Antares appoints Martin Campbell head of specialty - Reinsurance News
- Antares, the Lloyd’s platform of QIC Global, has appointed Martin Campbell head of specialty at Syndicate 1274. Campbell reports to Alexander Craggs,
- 05/14/2020
|
Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.
|
Previsão é de chuva nos próximos dias em Maceió
- Em caso de risco, população deve acionar Defesa Civil pelo número 199.
- 05/13/2020
|
HC Wainwright & Co. Maintains Buy on Antares Pharma, Lowers Price Target to $4.5
|
70 Biggest Movers From Yesterday
|
Antares Pharma Inc (ATRS) Q1 2020 Earnings Call Transcript
- Before we begin, I'd like to remind you that some of our statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The company cautions investors not to place undue reliance on these forward-looking statements.
- 05/06/2020
|
Antares Pharma shares are trading lower after the company reported Q1 earnings results.
|
Why Antares Pharma Is Crashing 12.3% Today
- After the company reported mixed first-quarter financial results that were better than expected on the top line and worse than expected on the bottom line, shares in Antares Pharma (NASDAQ: ATRS) had tumbled 12.3% at 12 p.m. EST on Tuesday. The healthcare company delivered robust revenue growth in Q1 because of Xyosted, a long-lasting testosterone drug, and Teva Pharmaceutical Industries' (NYSE: TEVA) generic version of Mylan's EpiPen, which uses Antares technology.
- 05/05/2020
|
51 Stocks Moving In Tuesday's Mid-Day Session
|
Antares Withdraws FY20 Guidance
|
Antares Pharma Q1 EPS $(0.010) Up From $(0.030) YoY, Sales $33.100M Beat $30.780M Estimate
|
Antares Pharma Reports First Quarter 2020 Operating and Financial Results
- First Quarter 2020 Revenue $33.1 Million, a 42% Increase Compared to First Quarter 2019 Generated $5.6 Million in Cash from Operations during the First Quarter 2020 EWING,.
- 05/05/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
Global Drug Delivery Technology Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025
- May 03, 2020 (CDN Newswire via Comtex) --
A new market research study titled Global Drug Delivery Technology Market 2020 by Company, Regions, Type and...
- 05/03/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Insights on the Worldwide Needle Free Drug Delivery Device Industry to 2024 - Featuring Antares Pharma, Injex Pharma & 3M Among Others
- Dublin, May 01, 2020 -- The "Needle Free Drug Delivery Device Market Report: Trends, Forecast, and Competitive Analysis" report has been added to.
- 05/01/2020
|
Antares Pharma (NASDAQ:ATRS) Upgraded by BidaskClub to Hold
- Antares Pharma (NASDAQ:ATRS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Thursday, BidAskClub reports. A number of other equities research analysts have also recently weighed in on the stock. Raymond James lifted their price objective on shares of Antares Pharma from $5.65 to […]
- 04/30/2020
|
Antares Pharma to Report First Quarter 2020 Operating and Financial Results
- EWING, N.J., April 28, 2020 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2020 financial results and recent operating progress before.
- 04/28/2020
|
Bank of America Corp DE Cuts Position in Antares Pharma Inc (NASDAQ:ATRS)
- Bank of America Corp DE trimmed its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 42.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 118,862 shares of the specialty pharmaceutical company’s stock after selling 87,686 shares during the […]
- 04/28/2020
|
Antares Pharma to Report First Quarter —…—… Operating and Financial Results
|
Analysts Offer Insights on Healthcare Companies: Flexion Therapeutics (FLXN) and Dexcom (DXCM)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Flexion Therapeutics (FLXN) and Dexcom (DXCM) with bullish
- 04/27/2020
|
Analysts Offer Insights on Healthcare Companies: Flexion Therapeutics (NASDAQ: FLXN) and Dexcom (NASDAQ: DXCM)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Flexion Therapeutics (
FLXN
–
Research Report
) and Dexcom (
DXCM
–
Research Report
) with bullish sentiments.
Flexion Therapeutics (FLXN)
In a report rele
- 04/27/2020
|
Assenagon Asset Management S.A. Buys New Shares in Antares Pharma Inc (NASDAQ:ATRS)
- Assenagon Asset Management S.A. bought a new stake in Antares Pharma Inc (NASDAQ:ATRS) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 23,410 shares of the specialty pharmaceutical company’s stock, valued at approximately $55,000. Several other hedge funds and other institutional […]
- 04/26/2020
|
$30.80 Million in Sales Expected for Antares Pharma Inc (NASDAQ:ATRS) This Quarter
- Wall Street brokerages expect Antares Pharma Inc (NASDAQ:ATRS) to announce $30.80 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Antares Pharma’s earnings, with the lowest sales estimate coming in at $26.90 million and the highest estimate coming in at $35.30 million. Antares Pharma posted sales of $23.29 […]
- 04/25/2020
|
FY2020 EPS Estimates for Antares Pharma Inc Lowered by Analyst (NASDAQ:ATRS)
- Antares Pharma Inc (NASDAQ:ATRS) – Equities researchers at Piper Sandler reduced their FY2020 earnings estimates for Antares Pharma in a research report issued on Monday, April 20th. Piper Sandler analyst D. Amsellem now expects that the specialty pharmaceutical company will post earnings per share of $0.11 for the year, down from their prior estimate of […]
- 04/24/2020
|
Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
- Emergent BioSolutions Inc. (EBS) today announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capability in clinical development, medical affairs, and regulatory affairs. Dr. Smith and
- 04/21/2020
|
Is Antares Pharma, Inc.’s (NASDAQ:ATRS) CEO Pay Justified?
- Bob Apple has been the CEO of Antares Pharma, Inc. (NASDAQ:ATRS) since 2016. First, this article will compare CEO...
- 04/21/2020
|
Geode Capital Management LLC Has $9.98 Million Stock Position in Antares Pharma Inc (NASDAQ:ATRS)
- Geode Capital Management LLC boosted its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,123,201 shares of the specialty pharmaceutical company’s stock after buying an additional 73,001 shares during the […]
- 04/21/2020
|
Exane Derivatives Invests $75,000 in Antares Pharma Inc (NASDAQ:ATRS)
- Exane Derivatives purchased a new position in shares of Antares Pharma Inc (NASDAQ:ATRS) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 31,811 shares of the specialty pharmaceutical company’s stock, valued at approximately $75,000. Several other large investors have also recently added […]
- 04/21/2020
|
Self-Administered Drugs Market to be Driven by Increasing Demand for Self-Injected Medical Devices, & Rising Technological Innovations in Drug Delivery Industry | Radiant Insights, Inc.
- Global Self-administered Drugs Market is anticipated to grow significantly in the coming years due to rise in number of chronic disorders. Self-administered drugs are the medications consumed by patients themselves without inhaling or injecting by the specialist. Some of the self-administered drugs comprise
- 04/21/2020
|
How To Get Away With Murder: The 10 Worst Things Michaela Ever Did
- Despite her usually upstanding demeanor, Michaela has done some pretty awful things in her time on How to Get Away with Murder.
- 04/19/2020
|
Bank of New York Mellon Corp Has $3.79 Million Stock Position in Antares Pharma Inc (NASDAQ:ATRS)
- Bank of New York Mellon Corp lifted its stake in Antares Pharma Inc (NASDAQ:ATRS) by 28.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 806,219 shares of the specialty pharmaceutical company’s stock after buying an additional 178,354 shares during the period. Bank […]
- 04/18/2020
|
Contrasting Sintx Technologies (NASDAQ:SINT) and Antares Pharma (NASDAQ:ATRS)
- Sintx Technologies (NASDAQ:SINT) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Insider & Institutional Ownership 0.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, […]
- 04/17/2020
|
AQR Capital Management LLC Decreases Holdings in Antares Pharma Inc (NASDAQ:ATRS)
- AQR Capital Management LLC lessened its stake in shares of Antares Pharma Inc (NASDAQ:ATRS) by 29.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,711 shares of the specialty pharmaceutical company’s stock after selling 19,792 shares during the period. AQR Capital Management LLC’s holdings in […]
- 04/13/2020
|
UBS Asset Management Americas Inc. Acquires 56,451 Shares of Antares Pharma Inc (NASDAQ:ATRS)
- UBS Asset Management Americas Inc. lifted its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 53.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 161,216 shares of the specialty pharmaceutical company’s stock after buying an additional 56,451 shares […]
- 04/12/2020
|
Cubist Systematic Strategies LLC Takes $423,000 Position in Antares Pharma Inc (NASDAQ:ATRS)
- Cubist Systematic Strategies LLC acquired a new position in shares of Antares Pharma Inc (NASDAQ:ATRS) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 89,975 shares of the specialty pharmaceutical company’s stock, valued at approximately $423,000. Cubist Systematic Strategies LLC owned approximately 0.06% of Antares […]
- 04/12/2020
|
Antares Pharma Inc (NASDAQ:ATRS) Shares Purchased by Goldman Sachs Group Inc.
- Goldman Sachs Group Inc. increased its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 211.9% during the fourth quarter, HoldingsChannel reports. The fund owned 1,081,480 shares of the specialty pharmaceutical company’s stock after buying an additional 734,783 shares during the period. Goldman Sachs Group Inc.’s holdings in Antares Pharma were worth $5,083,000 at the […]
- 04/09/2020
|
Tonight’s “Pink” Supermoon Will Be Biggest & Brightest of 2020
- The next full Moon is the Pink Moon, Sprouting Grass Moon, Egg Moon, Fish Moon, the Pesach or Passover Moon, Paschal Moon, Hanuman Jayanti, Bak Poya and a "supermoon." The Moon will be full on Tuesday night, April 7, 2020, appearing opposite the Sun (in Earth-based longitude) at 10:35 PM EDT. The
- 04/07/2020
|
Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.
|
Antares Pharma Inc (NASDAQ:ATRS) Shares Bought by Raymond James & Associates
- Raymond James & Associates raised its position in Antares Pharma Inc (NASDAQ:ATRS) by 177.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 115,909 shares of the specialty pharmaceutical company’s stock after purchasing an additional 74,204 shares during the quarter. Raymond James & Associates […]
- 04/06/2020
|
Credit Suisse AG Has $574,000 Holdings in Antares Pharma Inc (NASDAQ:ATRS)
- Credit Suisse AG increased its stake in Antares Pharma Inc (NASDAQ:ATRS) by 42.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 122,202 shares of the specialty pharmaceutical company’s stock after purchasing an additional 36,561 shares during the quarter. Credit Suisse AG owned approximately 0.07% […]
- 04/06/2020
|
Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.
|
Antares Pharma Inc (NASDAQ:ATRS) Stock Position Lowered by Baird Financial Group Inc.
- Baird Financial Group Inc. decreased its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 10.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 171,740 shares of the specialty pharmaceutical company’s stock after selling 20,061 shares during the quarter. Baird Financial Group Inc.’s holdings in Antares Pharma were worth $807,000 as of its […]
- 04/04/2020
|
Antares Pharma: An Undervalued Stock To Buy During The COVID-19 Crisis
- ATRS is trading over 50% below its 52-week high. The company has shown strong growth and will be cash flow positive in 2020. ATRS currently offers good value fo
- 04/03/2020
|
Brokerages Anticipate Antares Pharma Inc (NASDAQ:ATRS) Will Post Quarterly Sales of $30.90 Million
- Equities analysts expect Antares Pharma Inc (NASDAQ:ATRS) to post $30.90 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Antares Pharma’s earnings, with the lowest sales estimate coming in at $26.90 million and the highest estimate coming in at $35.70 million. Antares Pharma posted sales of $23.29 million during […]
- 04/02/2020
|
Global Needle Free Injection System Market Expected to Grow with a CAGR of16% During the Period, 2019-2024 - ResearchAndMarkets.com
- The "Needle Free Injection System Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.
- 04/01/2020
|
Envestnet Asset Management Inc. Has $292,000 Position in Antares Pharma Inc (NASDAQ:ATRS)
- Envestnet Asset Management Inc. boosted its stake in shares of Antares Pharma Inc (NASDAQ:ATRS) by 18.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,167 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,689 shares during the […]
- 04/01/2020
|
New herbicide options for 2020
- Control weeds such as waterhemp and Palmer amaranth with new formulations.
- 04/01/2020
|
Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.
|
From quills to qwerty: Lloyd’s underwriters adapt to home working
- LONDON — Thousands of London’s underwriters took their stamps and fountain pens home last week, which they use to sign insurance contracts, but they won’t need them.Working at hom…
- 03/30/2020
|
RPT-FOCUS-From quills to qwerty: Lloyd's underwriters adapt to home working
- (Repeats story published on Friday)
- 03/30/2020
|
From quills to qwerty: Lloyd’s underwriters adapt to home working
- LONDON — Thousands of London’s underwriters took their stamps and fountain pens home last week, which they use to sign insurance contracts, but they won’t need them.Working at hom…
- 03/29/2020
|
Antares Pharma (NASDAQ:ATRS) Trading Down 5%
- Antares Pharma Inc (NASDAQ:ATRS)’s stock price was down 5% during mid-day trading on Friday . The company traded as low as $2.01 and last traded at $2.09, approximately 1,801,107 shares were traded during mid-day trading. An increase of 7% from the average daily volume of 1,690,983 shares. The stock had previously closed at $2.20. Several […]
- 03/29/2020
|
Antares Pharma (NASDAQ:ATRS) versus Integra Lifesciences (NASDAQ:IART) Head-To-Head Contrast
- Antares Pharma (NASDAQ:ATRS) and Integra Lifesciences (NASDAQ:IART) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Earnings and Valuation This table compares Antares Pharma and Integra Lifesciences’ gross revenue, earnings per share […]
- 03/29/2020
|
Prudential Financial Inc. Buys 5,057 Shares of Antares Pharma Inc (NASDAQ:ATRS)
- Prudential Financial Inc. lifted its stake in shares of Antares Pharma Inc (NASDAQ:ATRS) by 34.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 19,747 shares of the specialty pharmaceutical company’s stock after buying an additional 5,057 shares during the quarter. Prudential Financial Inc.’s holdings in Antares Pharma were worth $93,000 as of its […]
- 03/28/2020
|
From quills to qwerty: Lloyd's underwriters adapt to home working
- Thousands of London's underwriters took their stamps and fountain pens home last week, which they use to sign insurance contracts, but they won't need them. Working at home due to the coronavirus lockdown, they have abandoned the normal tools of their trade and are turning to email and other
- 03/28/2020
|
From quills to qwerty: Lloyd's underwriters adapt to home working
- Thousands of London's underwriters took their stamps and fountain pens home last week, which they use to sign insurance contracts, but they won't need them. Working at home due to the coronavirus lockdown, they have abandoned the normal tools of their trade and are turning to email and other
- 03/27/2020
|
From quills to qwerty: Lloyd’s underwriters adapt to home working
- LONDON — Thousands of London’s underwriters took their stamps and fountain pens home last week, which they use to sign insurance contracts, but they won’t need them.Working at hom…
- 03/27/2020
|
FOCUS-From quills to qwerty: Lloyd's underwriters adapt to home working
- Thousands of London's underwriters took their stamps and fountain pens home last week, which they use to sign insurance contracts, but they won't need them. Working at home due to the coronavirus lockdown, they have abandoned the normal tools of their trade and are turning to email and other
- 03/27/2020
|
Antares Pharma Inc (NASDAQ:ATRS) Short Interest Down 24.2% in March
- Antares Pharma Inc (NASDAQ:ATRS) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totalling 4,735,600 shares, a drop of 24.2% from the February 27th total of 6,250,000 shares. Currently, 3.1% of the shares of the company are sold short. Based on […]
- 03/27/2020
|
Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.
|
Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?
- Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- 03/26/2020
|
Antares Pharma (NASDAQ:ATRS) Upgraded to "Sell" at BidaskClub
- Antares Pharma (NASDAQ:ATRS) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Thursday, BidAskClub reports. Several other brokerages also recently commented on ATRS. ValuEngine downgraded shares of Antares Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. HC […]
- 03/26/2020
|
Bank of Montreal Can Has $96,000 Position in Antares Pharma Inc (NASDAQ:ATRS)
- Bank of Montreal Can increased its position in Antares Pharma Inc (NASDAQ:ATRS) by 43.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,426 shares of the specialty pharmaceutical company’s stock after buying an additional 6,236 shares during the period. Bank of Montreal Can’s holdings in […]
- 03/26/2020
|
Antares Pharma Inc (NASDAQ:ATRS) Stake Raised by Advisor Group Inc.
- Advisor Group Inc. increased its holdings in Antares Pharma Inc (NASDAQ:ATRS) by 11.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,997 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,749 shares during the period. Advisor […]
- 03/26/2020
|
Firefly targets summer launch, unveils plans for lunar delivery service
- Company pressing ahead despite COVID-19 pandemic.
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Panagora Asset Management Inc. Purchases Shares of 22,840 Antares Pharma Inc (NASDAQ:ATRS)
- Panagora Asset Management Inc. purchased a new stake in shares of Antares Pharma Inc (NASDAQ:ATRS) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 22,840 shares of the specialty pharmaceutical company’s stock, valued at approximately $107,000. A number of other hedge funds also recently added […]
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Stocks That Hit 52-Week Lows On Monday
- On Monday morning, 720 companies hit new 52-week lows.
Noteworthy Mentions:
The largest company by market cap to set a new 52-week low was Alphabet (NASDAQ: GOOGL)...
- 03/23/2020
|
Antares Pharma Inc (NASDAQ:ATRS) Shares Acquired by Mercer Global Advisors Inc. ADV
- Mercer Global Advisors Inc. ADV increased its position in Antares Pharma Inc (NASDAQ:ATRS) by 22.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 55,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,225 shares during the period. Mercer Global Advisors Inc. ADV’s holdings […]
- 03/23/2020
|
How the RBA’s Easing Backfired in a Flash Crash for Aussie Bonds
- (Bloomberg) -- Just when investors thought central banks were beginning to calm a global bond rout, the epicenter of chaos shifted to Australia as its market went into meltdown on March 19. The trigger was the announcement of the country’s own quantitative easing program, which should have soothed nerves
- 03/22/2020
|
Edited Transcript of ATRS earnings conference call or presentation 3-Mar-20 1:30pm GMT
- Q4 2019 Antares Pharma Inc Earnings Call
- 03/22/2020
|
Edited Transcript of ATRS earnings conference call or presentation 3-Mar-20 1:30pm GMT
- Q4 2019 Antares Pharma Inc Earnings Call
- 03/22/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
Stocks That Hit 52-Week Lows On Thursday
- On Thursday morning, 1178 companies hit new 52-week lows.
Facts of Interest:
The largest company by market cap to set a new 52-week low was Nuveen Preferred & Income...
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
EANS-Kapitalmarktinformation: Atrium European Real Estate Limited / Bekanntgaben zu Rückkaufprogrammen (Artikel 5 MAR)
- ATRIUM EUROPEAN REAL ESTATE BESCHLIESST RÜCKKAUFPROGRAMM VON BIS ZU 25 MILLIONEN AKTIEN
- 03/17/2020
|
EANS-Other capital market information: Atrium European Real Estate Limited / Notification of share buyback transactions (Article 5 of Reg. (EU) market abuse)
- ATRIUM EUROPEAN REAL ESTATE RESOLVES TO UNDERTAKE BUY BACK PROGRAMME OF UP TO 25 MILLION SHARES
- 03/17/2020
|
Antares and Bain Capital Credit Support AE Industrial Partners’ Acquisition of G.S. Precision
- The Antares Bain Capital Complete Financing Solution (“ABCS”), a joint venture between Antares and Bain Capital Credit, today announced the closing of
- 03/16/2020
|
Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.
|
Starwatch: the moon and planets party till dawn
- Early risers in the northern hemisphere can see the crescent moon in the south-east in close conjunction with Mars, Jupiter and Saturn
- 03/15/2020
|
Antares Pharma Inc (NASDAQ:ATRS) Short Interest Update
- Antares Pharma Inc (NASDAQ:ATRS) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 6,250,000 shares, a growth of 12.0% from the February 13th total of 5,580,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is presently 4.4 days. Approximately 4.1% of […]
- 03/15/2020
|
Edited Transcript of BCSF.N earnings conference call or presentation 27-Feb-20 1:30pm GMT
- Q4 2019 Bain Capital Specialty Finance Inc Earnings Call
- 03/15/2020
|
Global Needle Free Injection System Market 2020 - Technology Landscape, Trends & Opportunities - ResearchAndMarkets.com
- The "Technology Landscape, Trends and Opportunities in the Global Needle Free Injection System Market" report has been added to ResearchAndMarkets.com's offering.
- 03/12/2020
|
Barclays PLC Buys 90,830 Shares of Antares Pharma Inc (NASDAQ:ATRS)
- Barclays PLC grew its stake in Antares Pharma Inc (NASDAQ:ATRS) by 90.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,986 shares of the specialty pharmaceutical company’s stock after acquiring an additional 90,830 shares during the period. Barclays PLC owned 0.12% […]
- 03/12/2020
|
Spaceflight Readies 28 Payloads for Inaugural Rideshare Launch on Arianespace’s Vega
- Spaceflight today announced it is providing mission management and rideshare integration services for four organizations on Arianespace’s first dedicated rideshare mission on its Vega launch vehicle. The proof of concept rideshare mission, VV16, will launch 53 microsatellites, nanosatellites and cubesats
- 03/09/2020
|
Barrier-Breaking Architect Says It’s Time for More Women in the Field
|
Zacks: Brokerages Anticipate Antares Pharma Inc (NASDAQ:ATRS) Will Post Quarterly Sales of $30.90 Million
- Equities analysts expect that Antares Pharma Inc (NASDAQ:ATRS) will post $30.90 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Antares Pharma’s earnings. The highest sales estimate is $35.70 million and the lowest is $26.90 million. Antares Pharma posted sales of $23.29 million in the same quarter last […]
- 03/09/2020
|
Starwatch: blood-red Antares, the brightest star in Scorpio
- This week will offer an opportunity to see the giant star that is 750 times the diameter of the sun
- 03/08/2020
|
Antares Pharma Inc Expected to Post Q2 2020 Earnings of $0.00 Per Share (NASDAQ:ATRS)
- Antares Pharma Inc (NASDAQ:ATRS) – Jefferies Financial Group lifted their Q2 2020 earnings per share estimates for shares of Antares Pharma in a report issued on Tuesday, March 3rd. Jefferies Financial Group analyst A. Petrone now anticipates that the specialty pharmaceutical company will post earnings per share of $0.00 for the quarter, up from their […]
- 03/08/2020
|
Antares Pharma Inc (NASDAQ:ATRS) Shares Sold by New York State Common Retirement Fund
- New York State Common Retirement Fund cut its stake in shares of Antares Pharma Inc (NASDAQ:ATRS) by 25.1% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 124,900 shares of the specialty pharmaceutical company’s stock after selling 41,900 shares during the period. New York State Common Retirement Fund […]
- 03/07/2020
|
Q1 2021 EPS Estimates for Antares Pharma Inc (NASDAQ:ATRS) Boosted by Piper Sandler
- Antares Pharma Inc (NASDAQ:ATRS) – Investment analysts at Piper Sandler boosted their Q1 2021 earnings per share (EPS) estimates for Antares Pharma in a research note issued on Tuesday, March 3rd. Piper Sandler analyst D. Amsellem now expects that the specialty pharmaceutical company will earn $0.07 per share for the quarter, up from their previous […]
- 03/07/2020
|
Antares Pharma (NASDAQ:ATRS) Stock Price Down 6.6%
- Antares Pharma Inc (NASDAQ:ATRS) traded down 6.6% on Friday . The stock traded as low as $3.17 and last traded at $3.24, 1,843,471 shares changed hands during trading. An increase of 18% from the average session volume of 1,566,726 shares. The stock had previously closed at $3.47. Several equities analysts have weighed in on the […]
- 03/07/2020
|
Piper Sandler Analysts Cut Earnings Estimates for Antares Pharma Inc (NASDAQ:ATRS)
- Antares Pharma Inc (NASDAQ:ATRS) – Analysts at Piper Sandler reduced their Q2 2020 earnings per share estimates for shares of Antares Pharma in a report released on Tuesday, March 3rd. Piper Sandler analyst D. Amsellem now anticipates that the specialty pharmaceutical company will earn $0.03 per share for the quarter, down from their previous estimate […]
- 03/06/2020
|
Antares Pharma (NASDAQ:ATRS) Shares Gap Up After Analyst Upgrade
- Antares Pharma Inc (NASDAQ:ATRS)’s stock price gapped up prior to trading on Thursday after Raymond James raised their price target on the stock from $5.65 to $6.00. The stock had previously closed at $3.56, but opened at $3.38. Raymond James currently has a strong-buy rating on the stock. Antares Pharma shares last traded at $3.40, […]
- 03/06/2020
|
Antares Pharma (NASDAQ:ATRS) Shares Up 8.7% Following Analyst Upgrade
- Antares Pharma Inc (NASDAQ:ATRS)’s share price shot up 8.7% during trading on Wednesday after Raymond James raised their price target on the stock from $5.65 to $6.00. Raymond James currently has a strong-buy rating on the stock. Antares Pharma traded as high as $3.44 and last traded at $3.38, 2,335,961 shares traded hands during trading. […]
- 03/06/2020
|
Antares Pharma (NASDAQ:ATRS) Releases Earnings Results
- Antares Pharma (NASDAQ:ATRS) posted its earnings results on Tuesday. The specialty pharmaceutical company reported $0.03 EPS for the quarter, Bloomberg Earnings reports. The business had revenue of $37.84 million during the quarter, compared to analyst estimates of $34.35 million. Antares Pharma had a negative return on equity of 4.73% and a negative net margin of […]
- 03/05/2020
|
Antares Pharma, Inc. Just Released Its Full-Year Earnings: Here’s What Analysts Think
- It's been a pretty great week for Antares Pharma, Inc. (NASDAQ:ATRS) shareholders, with its shares surging 13% to...
- 03/05/2020
|
Antares Pharma (NASDAQ:ATRS) Trading 8.7% Higher on Analyst Upgrade
- Antares Pharma Inc (NASDAQ:ATRS) shares traded up 8.7% on Wednesday after Raymond James raised their price target on the stock from $5.65 to $6.00. Raymond James currently has a strong-buy rating on the stock. Antares Pharma traded as high as $3.44 and last traded at $3.38, 2,335,961 shares changed hands during trading. An increase of […]
- 03/05/2020
|
Stargazing in March: Snow-white Pluto and the eight dwarfs
- Celebrate 90 years since the planet was discovered with a rare chance to glimpse one of the iciest places in the solar system
- 03/04/2020
|
Analysts Are Bullish on These Healthcare Stocks: Antares Pharma (ATRS), Durect (DRRX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (ATRS) and Durect (DRRX) with bullish
- 03/04/2020
|
Analysts Are Bullish on These Healthcare Stocks: Antares Pharma (ATRS), Durect (DRRX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (
ATRS
–
Research Report
) and Durect (
DRRX
–
Research Report
) with bullish sentiments.
Antares Pharma (ATRS)
In a report released today,
- 03/04/2020
|
122,622 Shares in Antares Pharma Inc (NASDAQ:ATRS) Acquired by Advisory Research Inc.
- Advisory Research Inc. purchased a new position in shares of Antares Pharma Inc (NASDAQ:ATRS) in the 4th quarter, Holdings Channel reports. The firm purchased 122,622 shares of the specialty pharmaceutical company’s stock, valued at approximately $576,000. A number of other hedge funds also recently modified their holdings of the stock. State Street Corp increased its […]
- 03/04/2020
|
Antares Pharma Inc (ATRS) Q4 2019 Earnings Call Transcript
- ATRS earnings call for the period ending December 31, 2019.
- 03/04/2020
|
Raymond James Maintains Strong Buy on Antares Pharma, Raises Price Target to $6
|
Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript
- Antares Pharma, Inc. (NASDAQ:ATRS) Q4 2019 Results Earnings Conference Call March 03, 2020 08:30 AM ET Company Participants Jack Howarth - Vice President of Cor
- 03/03/2020
|
How Antares Pharma Beat Expectations in Q4
- Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.
- 03/03/2020
|
Antares Pharma Reports Q4 and Full Year 2019 Financial Results
- Antares Pharma reported operating and financial results for the fourth quarter and full year ended December 31, 2019. The post Antares Pharma Reports Q4 and Full Year 2019 Financial Results appeared first on Investing News Network .
- 03/03/2020
|
40 Healthcare Stocks Moving In Tuesday's Pre-Market Session
- Gainers
Stealth BioTherapeutics, Inc. (NASDAQ: MITO) shares surged 74.2% to $3.31 during Tuesday's pre-market session. According to the most recent rating by H.C....
- 03/03/2020
|
The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
- 03/03/2020
|
Antares Pharma: 4Q Earnings Snapshot
- EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported fourth-quarter profit of $4.7 million.
The Ewing, New Jersey-based company said it had profit of 3 cents per share.
The results surpassed Wall Street expectations. The average estimate
- 03/03/2020
|
Antares Pharma reaffirms FY20 revenue view $135M-$155M, consensus $147.56M ATRS
- Antares Pharma reaffirms FY20 revenue view $135M-$155M, consensus $147.56M ATRS
- 03/03/2020
|
Antares Pharma reports Q4 EPS 3c, consensus 0c ATRS
- Antares Pharma reports Q4 EPS 3c, consensus 0c ATRS
- 03/03/2020
|
Antares Pharma Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
- Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03 Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue EWING, N.J., March.
- 03/03/2020
|
Antares Pharma Reports Fourth Quarter and Full Year 2019 Operating and Financial Results
- Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03 Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue ...
- 03/03/2020
|
Seabury Capital Advises Aurelius on Acquisition of German Aircraft Seat Manufacturer Zim Flugsitz
- Seabury Capital advises Aurelius on the acquisition of German manufacturer Zim Flugsitz, marking Aurelius’ entry into the aircraft interior niche.
- 03/02/2020
|
Health Check: How Prudently Does Antares Pharma (NASDAQ:ATRS) Use Debt?
- Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- 03/01/2020
|
